Literature DB >> 34218683

What do we do with our under-enrolled single-center COVID-19 clinical trials?

Shing M Lee1, Denise Esserman2, Ken Cheung1, James Dziura2, Peter Peduzzi2, Magdalena Sobieszczyk3.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34218683      PMCID： PMC8595488          DOI： 10.1177/17407745211027246

Source DB:  PubMed          Journal:  Clin Trials        ISSN： 1740-7745            Impact factor:   2.599


× No keyword cloud information.
  8 in total

1.  Pooling Data From Individual Clinical Trials in the COVID-19 Era.

Authors:  Eva Petkova; Elliott M Antman; Andrea B Troxel
Journal:  JAMA       Date:  2020-08-11       Impact factor: 56.272

2.  Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.

Authors:  Janet Woodcock; Lisa M LaVange
Journal:  N Engl J Med       Date:  2017-07-06       Impact factor: 91.245

3.  Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An Unprecedented Partnership for Unprecedented Times.

Authors:  Francis S Collins; Paul Stoffels
Journal:  JAMA       Date:  2020-05-18       Impact factor: 56.272

4.  The continuing unethical conduct of underpowered clinical trials.

Authors:  Scott D Halpern; Jason H T Karlawish; Jesse A Berlin
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

Review 5.  Clinical trials in the time of a pandemic.

Authors:  Susan S Ellenberg
Journal:  Clin Trials       Date:  2020-07-10       Impact factor: 2.486

6.  Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Marion Mafham; Louise Linsell; Jennifer L Bell; Natalie Staplin; Jonathan R Emberson; Martin Wiselka; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Tony Whitehouse; Timothy Felton; John Williams; Jakki Faccenda; Jonathan Underwood; J Kenneth Baillie; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Wei Shen Lim; Alan Montgomery; Kathryn Rowan; Joel Tarning; James A Watson; Nicholas J White; Edmund Juszczak; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-10-08       Impact factor: 91.245

7.  Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks.

Authors:  Natalie E Dean; Pierre-Stéphane Gsell; Ron Brookmeyer; Forrest W Crawford; Christl A Donnelly; Susan S Ellenberg; Thomas R Fleming; M Elizabeth Halloran; Peter Horby; Thomas Jaki; Philip R Krause; Ira M Longini; Sabue Mulangu; Jean-Jacques Muyembe-Tamfum; Martha C Nason; Peter G Smith; Rui Wang; Ana M Henao-Restrepo; Victor De Gruttola
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 176.079

8.  Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.

Authors:  Christina M Eckhardt; Matthew J Cummings; Kartik N Rajagopalan; Sarah Borden; Zachary C Bitan; Allison Wolf; Alex Kantor; Thomas Briese; Benjamin J Meyer; Samuel D Jacobson; Dawn Scotto; Nischay Mishra; Neena M Philip; Brie A Stotler; Joseph Schwartz; Beth Shaz; Steven L Spitalnik; Andrew Eisenberger; Eldad A Hod; Jessica Justman; Ken Cheung; W Ian Lipkin; Max R O'Donnell
Journal:  Trials       Date:  2020-06-08       Impact factor: 2.279
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.